bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S3 from Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer
Authors: Guan Xiangnan , Sun Duanchen , Lu Eric , Urrutia Joshua A. , Reiter Robert Evan , Rettig Matthew , Evans Christopher P. , Lara Primo , Gleave Martin , Beer Tomasz M. , Thomas George V. , Huang Jiaoti , Aggarwal Rahul R. , Quigley David A. , Foye Adam , Chen William S. , Youngren Jack , Weinstein Alana S. , Stuart Joshua M. , Feng Felix Y. , Small Eric J. , Xia Zheng , Alumkal Joshi J.
Published: April 2023

Figure S3 shows the prognostic significance of copy number loss of 17q24, 2q24, and 4q35 containing putative tumor suppressor genes.
Supplementary Data from Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer
Authors: Wang Fei , Reid Sonya , Zheng Wei , Pal Tuya , Meszoely Ingrid , Mayer Ingrid A. , Bailey Christina E. , Park Ben Ho , Shu Xiao-Ou
Published: April 2023

Supplementary Table S1. Characteristics of male breast cancer patients by receipt of Oncotype DX Recurrence Score (RS) testing Supplementary Table S2. HRs (95% CI) for total mortality associated with the Recurrence Score categories among patients {less than or equal to} 50 years Supplementary Table S3. HRs (95% CI) for total mortality associated with the Recurrence Score categories among patients > 50 years Supplementary Table S4. HRs (95% CI) for total mortality associated with chemotherapy status among intermediate-risk patients by age Supplementary Table S5. HRs (95% CI) for total mortality associated with Recurrence Score categories (sensitivity analysis)
Supplemental Legend from The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial
Authors: Santa-Maria Cesar A. , Coughlin Janelle W. , Sharma Dipali , Armanios Mary , Blackford Amanda L. , Schreyer Colleen , Dalcin Arlene , Carpenter Ashley , Jerome Gerald J. , Armstrong Deborah K. , Chaudhry Madhu , Cohen Gary I. , Connolly Roisin M. , Fetting John , Miller Robert S. , Smith Karen L. , Snyder Claire , Wolfe Andrew , Wolff Antonio C. , Huang Chiung-Yu , Appel Lawrence J. , Stearns Vered
Published: April 2023

Supplemental Legend
Supplementary Data from Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
Authors: Sweet Kendra , Komrokji Rami , Padron Eric , Cubitt Christopher L. , Turner Joel G. , Zhou Junmin , List Alan F. , Sallman David A. , Dawson Jana L. , Sullivan Daniel M. , Chavez Julio , Shah Bijal D. , Lancet Jeffrey E.
Published: April 2023

Supplementary Methods.
Supplementary Table ST4 from Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial
Authors: Rodriguez Gutierrez Daniel , Jones Chris , Varlet Pascale , Mackay Alan , Warren Daniel , Warmuth-Metz Monika , Aliaga Esther Sánchez , Calmon Raphael , Hargrave Darren R. , Cañete Adela , Massimino Maura , Azizi Amedeo A. , Le Deley Marie-Cécile , Saran Frank , Rousseau Raphael F. , Zahlmann Gudrun , Garcia Josep , Vassal Gilles , Grill Jacques , Morgan Paul S. , Jaspan Tim
Published: April 2023

Resection rates for tumor grades
Supplementary Figure S1 from A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer
Authors: Tolaney Sara M. , Sahebjam Solmaz , Le Rhun Emilie , Bachelot Thomas , Kabos Peter , Awada Ahmad , Yardley Denise , Chan Arlene , Conte Pierfranco , Diéras Véronique , Lin Nancy U. , Bear Melissa , Chapman Sonya C. , Yang Zhengyu , Chen Yanyun , Anders Carey K.
Published: April 2023

Change in intracranial (Panel A) and extracranial (Panel B) tumor size and best overall response, and duration of exposure to abemaciclib (Panel C) in cohort B (HR+, HER2+ MBC). Note: Patients who did not have a post-baseline scan (for intracranial), or who did not have an extracranial lesion or a post-baseline scan (for extracranial) are not shown on waterfall plots. oIndicates patient received prior whole brain radiotherapy. +Indicates patient received prior stereotactic radiosurgery. #Indicates patient received concomitant endocrine therapy. ^Indicates patient received concomitant trastuzumab. Abbreviations: CR, complete response; HER2+/â^', human epidermal growth factor receptor-2 positive/negative; HR+, hormone receptor positive; MBC, metastatic breast cancer; NE, not estimable; PD, progressive disease; PR, partial response; SD, stable disease.
Supplementary Figure 3 from Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers
Authors: Høgdall Dan , O'Rourke Colm J. , Dehlendorff Christian , Larsen Ole F. , Jensen Lars H. , Johansen Astrid Z. , Dang Hien , Factor Valentina M. , Grunnet Mie , Mau-Sørensen Morten , Oliveira Douglas V.N.P. , Linnemann Dorte , Boisen Mogens K. , Wang Xin W. , Johansen Julia S. , Andersen Jesper B.
Published: April 2023

Supplementary Figure 3: Effects of gemcitabine treatment on IL6(R) expression in vitro, impact of IL-6R and YKL-40 inhibition in BTC cell lines in vitro, expression of IL6(R) in BTC patient tumors.
Supplementary Figure S1 from Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study
Authors: Harrington Kevin J. , Kong Anthony , Mach Nicolas , Chesney Jason A. , Fernandez Beatriz Castelo , Rischin Danny , Cohen Ezra E.W. , Radcliffe Hoi-Shen , Gumuscu Burak , Cheng Jonathan , Snyder Wendy , Siu Lillian L.
Published: April 2023

Change from baseline in tumor burden of target lesions at patient level
Supplementary Data from Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial)
Authors: Kawazoe Akihito , Kuboki Yasutoshi , Shinozaki Eiji , Hara Hiroki , Nishina Tomohiro , Komatsu Yoshito , Yuki Satoshi , Wakabayashi Masashi , Nomura Shogo , Sato Akihiro , Kuwata Takeshi , Kawazu Masahito , Mano Hiroyuki , Togashi Yosuke , Nishikawa Hiroyoshi , Yoshino Takayuki
Published: April 2023

Supplementary Data
Figure S1 from Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial)
Authors: Kawazoe Akihito , Kuboki Yasutoshi , Shinozaki Eiji , Hara Hiroki , Nishina Tomohiro , Komatsu Yoshito , Yuki Satoshi , Wakabayashi Masashi , Nomura Shogo , Sato Akihiro , Kuwata Takeshi , Kawazu Masahito , Mano Hiroyuki , Togashi Yosuke , Nishikawa Hiroyoshi , Yoshino Takayuki
Published: April 2023

Figure S1. Consort diagram
Supplementary Data from Potent Activity of an Anti-ICAM1 Antibody–Drug Conjugate against Multiple Myeloma
Authors: Sherbenou Daniel W. , Su Yang , Behrens Christopher R. , Aftab Blake T. , Perez de Acha Olivia , Murnane Megan , Bearrows Shelby C. , Hann Byron C. , Wolf Jeffery L. , Martin Thomas G. , Liu Bin
Published: April 2023

Supplementary Tables and Figures
Supplementary Figure 3 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Authors: Janku Filip , Park Haeseong , Call S. Greg , Madwani Kiran , Oki Yasuhiro , Subbiah Vivek , Hong David S. , Naing Aung , Velez-Bravo Vivianne M. , Barnes Tamara G. , Hagemeister Fredrick B. , Falchook Gerald S. , Karp Daniel D. , Wheler Jennifer J. , Piha-Paul Sarina A. , Garrido-Laguna Ignacio , Shpall Elizabeth J. , Fayad Luis E. , Neelapu Sattva S. , Meric-Bernstam Funda , Kurzrock Razelle , Fanale Michelle A.
Published: April 2023

Representative images of selected patients with therapy response.
Table S1 from Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma
Authors: Algazi Alain P. , Twitty Christopher G. , Tsai Katy K. , Le Mai , Pierce Robert , Browning Erica , Hermiz Reneta , Canton David A. , Bannavong Donna , Oglesby Arielle , Francisco Murray , Fong Lawrence , Pittet Mikael J. , Arlauckas Sean P. , Garris Christopher , Levine Lauren P. , Bifulco Carlos , Ballesteros-Merino Carmen , Bhatia Shailender , Gargosky Sharron , Andtbacka Robert H.I. , Fox Bernard A. , Rosenblum Michael D. , Daud Adil I.
Published: April 2023

Fluorescence-conjugated antibody used for flow cytometry
Supplementary Figure Legends from Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma
Authors: Algazi Alain P. , Twitty Christopher G. , Tsai Katy K. , Le Mai , Pierce Robert , Browning Erica , Hermiz Reneta , Canton David A. , Bannavong Donna , Oglesby Arielle , Francisco Murray , Fong Lawrence , Pittet Mikael J. , Arlauckas Sean P. , Garris Christopher , Levine Lauren P. , Bifulco Carlos , Ballesteros-Merino Carmen , Bhatia Shailender , Gargosky Sharron , Andtbacka Robert H.I. , Fox Bernard A. , Rosenblum Michael D. , Daud Adil I.
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 8 from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Authors: Uppaluri Ravindra , Campbell Katie M. , Egloff Ann Marie , Zolkind Paul , Skidmore Zachary L. , Nussenbaum Brian , Paniello Randal C. , Rich Jason T. , Jackson Ryan , Pipkorn Patrik , Michel Loren S. , Ley Jessica , Oppelt Peter , Dunn Gavin P. , Barnell Erica K. , Spies Nicholas C. , Lin Tianxiang , Li Tiantian , Mulder David T. , Hanna Youstina , Cirlan Iulia , Pugh Trevor J. , Mudianto Tenny , Riley Rachel , Zhou Liye , Jo Vickie Y. , Stachler Matthew D. , Hanna Glenn J. , Kass Jason , Haddad Robert , Schoenfeld Jonathan D. , Gjini Evisa , Lako Ana , Thorstad Wade , Gay Hiram A. , Daly Mackenzie , Rodig Scott J. , Hagemann Ian S. , Kallogjeri Dorina , Piccirillo Jay F. , Chernock Rebecca D. , Griffith Malachi , Griffith Obi L. , Adkins Douglas R.
Published: April 2023

Supplementary Figure
Supplementary Tables from Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results
Authors: Ferrarotto Renata , Bell Diana , Rubin Maria L. , Hutcheson Katherine A. , Johnson Jason M. , Goepfert Ryan P. , Phan Jack , Elamin Yasir Y. , Torman Danice K. , Warneke Carla L. , Hessel Amy C. , Garden Adam S. , Myers Jeffrey N. , Johnson Faye M. , Lee J. Jack , Sikora Andrew G. , Gillison Maura L. , Glisson Bonnie S. , Gross Neil D.
Published: April 2023

Supplementary Tables
Supplementary Data Table from The Nanocind Signature Is an Independent Prognosticator of Recurrence and Death in Uterine Leiomyosarcomas
Authors: Croce Sabrina , Lesluyes Tom , Valle Carine , M'Hamdi Loubna , Thébault Noémie , Pérot Gaëlle , Stoeckle Eberhard , Noël Jean-Christophe , Fontanges Quitterie , Devouassoux-Shisheboran Mojgan , Querleu Denis , Guyon Frédéric , Floquet Anne , Chakiba Camille , Mayeur Laetitia , Rebier Flora , MacGrogan Gaëtan Marie , Soubeyran Isabelle , Le Guellec Sophie , Chibon Frédéric
Published: April 2023

Table. Clinico-morphologic and genomic data.
Supplementary Table S2 from Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib
Authors: Fraunhoffer Nicolas A. , Abuelafia Analía Meilerman , Bigonnet Martin , Gayet Odile , Roques Julie , Telle Emmanuel , Santofimia-Castaño Patricia , Borrello María Teresa , Chuluyan Eduardo , Dusetti Nelson , Iovanna Juan
Published: April 2023

Supplementary Table S2
Supplementary Data 1 from Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma
Authors: Bachet Jean-Baptiste , Blons Hélène , Hammel Pascal , Hariry Iman El , Portales Fabienne , Mineur Laurent , Metges Jean-Philippe , Mulot Claire , Bourreau Camille , Cain Jason , Cros Jérôme , Laurent-Puig Pierre
Published: April 2023

Description of the studied population
Table S4 from TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
Authors: Rosen Ezra Y. , Goldman Debra A. , Hechtman Jaclyn F. , Benayed Ryma , Schram Alison M. , Cocco Emiliano , Shifman Sophie , Gong Yixiao , Kundra Ritika , Solomon James P. , Bardelli Alberto , Scaltriti Maurizio , Drilon Alexander , Iasonos Alexia , Taylor Barry S. , Hyman David M.
Published: April 2023

Supplemental Table 4. Patient level detail of use of immunotherapy in this cohort.
Figure S6 from TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
Authors: Rosen Ezra Y. , Goldman Debra A. , Hechtman Jaclyn F. , Benayed Ryma , Schram Alison M. , Cocco Emiliano , Shifman Sophie , Gong Yixiao , Kundra Ritika , Solomon James P. , Bardelli Alberto , Scaltriti Maurizio , Drilon Alexander , Iasonos Alexia , Taylor Barry S. , Hyman David M.
Published: April 2023

Supplemental Figure 6. Distribution of Surgery, Radiotherapy, Systemic Therapy, and Chemotherapy.
Figure S2 from TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
Authors: Rosen Ezra Y. , Goldman Debra A. , Hechtman Jaclyn F. , Benayed Ryma , Schram Alison M. , Cocco Emiliano , Shifman Sophie , Gong Yixiao , Kundra Ritika , Solomon James P. , Bardelli Alberto , Scaltriti Maurizio , Drilon Alexander , Iasonos Alexia , Taylor Barry S. , Hyman David M.
Published: April 2023

Supplemental Figure 2. Age Distribution of Patients in the MSK TRK Cohort.
Supplementary Fig. S1 from Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression
Authors: Tanimoto Azusa , Matsumoto Shingo , Takeuchi Shinji , Arai Sachiko , Fukuda Koji , Nishiyama Akihiro , Yoh Kiyotaka , Ikeda Takaya , Furuya Naoki , Nishino Kazumi , Ohe Yuichiro , Goto Koichi , Yano Seiji
Published: April 2023

CONSORT diagram.
Supplementary Table 1 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
Authors: LeBlanc Amy K. , Mazcko Christina N. , Cherukuri Aswini , Berger Erika P. , Kisseberth William C. , Brown Megan E. , Lana Susan E. , Weishaar Kristen , Flesner Brian K. , Bryan Jeffrey N. , Vail David M. , Burton Jenna H. , Willcox Jennifer L. , Mutsaers Anthony J. , Woods J. Paul , Northrup Nicole C. , Saba Corey , Curran Kaitlin M. , Leeper Haley , Wilson-Robles Heather , Wustefeld-Janssens Brandan G. , Lindley Stephanie , Smith Annette N. , Dervisis Nikolaos , Klahn Shawna , Higginbotham Mary Lynn , Wouda Raelene M. , Krick Erika , Mahoney Jennifer A. , London Cheryl A. , Barber Lisa G. , Balkman Cheryl E. , McCleary-Wheeler Angela L. , Suter Steven E. , Martin Olya , Borgatti Antonella , Burgess Kristine , Childress Michael O. , Fidel Janean L. , Allstadt Sara D. , Gustafson Daniel L. , Selmic Laura E. , Khanna Chand , Fan Timothy M.
Published: April 2023

Supplementary Table 1 contains the inclusion and exclusion criteria for pet dogs considered for enrollment into the SOC and SOC + S clinical trial arms.
Figure S4 from Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor
Authors: Ogura Koichi , Somwar Romel , Hmeljak Julija , Magnan Heather , Benayed Ryma , Momeni Boroujeni Amir , Bowman Anita S. , Mattar Marissa S. , Khodos Inna , de Stanchina Elisa , Jungbluth Achim , Asher Marina , Odintsov Igor , Hartono Alifiani B. , LaQuaglia Michael P. , Slotkin Emily , Pratilas Christine A. , Lee Sean Bong , Spraggon Lee , Ladanyi Marc
Published: April 2023

Supplementary Figure 4. Normalized expression of ALK and ROS1 in patient samples.
Figure S1 from Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor
Authors: Ogura Koichi , Somwar Romel , Hmeljak Julija , Magnan Heather , Benayed Ryma , Momeni Boroujeni Amir , Bowman Anita S. , Mattar Marissa S. , Khodos Inna , de Stanchina Elisa , Jungbluth Achim , Asher Marina , Odintsov Igor , Hartono Alifiani B. , LaQuaglia Michael P. , Slotkin Emily , Pratilas Christine A. , Lee Sean Bong , Spraggon Lee , Ladanyi Marc
Published: April 2023

Supplementary Figure 1. Western blot analysis using WT1 C-terminal antibody.
Supplementary Data from Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET
Authors: Wang Sinan , Li Jun , Hua Jun , Su Yang , Beckford-Vera Denis R. , Zhao Walter , Jayaraman Mayuri , Huynh Tony L. , Zhao Ning , Wang Yung-hua , Huang Yangjie , Qin Fujun , Shen Sui , Gioeli Daniel , Dreicer Robert , Sriram Renuka , Egusa Emily A. , Chou Jonathan , Feng Felix Y. , Aggarwal Rahul , Evans Michael J. , Seo Youngho , Liu Bin , Flavell Robert R. , He Jiang
Published: April 2023

Supplemental
Supplementary Materials from Development of a Histopathology Informatics Pipeline for Classification and Prediction of Clinical Outcomes in Subtypes of Renal Cell Carcinoma
Authors: Marostica Eliana , Barber Rebecca , Denize Thomas , Kohane Isaac S. , Signoretti Sabina , Golden Jeffrey A. , Yu Kun-Hsing
Published: April 2023

Supplementary Materials
Supplementary Figure S2 from First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas
Authors: Gopal Ajay K. , Levy Ronald , Houot Roch , Patel Sandip P. , Popplewell Leslie , Jacobson Caron , Mu Xinmeng J. , Deng Shibing , Ching Keith A. , Chen Ying , Davis Craig B. , Huang Bo , Fly Kolette D. , Thall Aron , Woolfson Adrian , Bartlett Nancy L.
Published: April 2023

Immune cell fractions derived from flow cytometry were highly concordant with those derived from RNA-Seq deconvolution in baseline blood samples from patients with follicular lymphoma. Pearson correlations were computed for each immune subset. Solid lines were fitted using linear regression.
Supplementary Legend from A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer
Authors: Kazmi Farasat , Nicum Shibani , Roux Rene L. , Spiers Laura , Gnanaranjan Chat , Sukumaran Ajithkumar , Gabra Hani , Ghazaly Essam , McCracken Nigel W. , Harrison David J. , Blagden Sarah P.
Published: April 2023

Supplementary Legend
Figure S1 from A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer
Authors: Kazmi Farasat , Nicum Shibani , Roux Rene L. , Spiers Laura , Gnanaranjan Chat , Sukumaran Ajithkumar , Gabra Hani , Ghazaly Essam , McCracken Nigel W. , Harrison David J. , Blagden Sarah P.
Published: April 2023

Scheme of base PK model for NUC-1031, dFdC and dFdU
Table S6 from Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer
Authors: Yu Helena A. , Paz-Ares Luis G. , Yang James Chih-Hsin , Lee Ki Hyeong , Garrido Pilar , Park Keunchil , Kim Joo-Hang , Lee Dae Ho , Mao Huzhang , Wijayawardana Sameera R. , Gao Ling , Hozak Rebecca R. , Chao Bo H. , Planchard David
Published: April 2023

Ramucirumab Serum Concentrations After Ramucirumab Administration
Supplementary Data 1 from Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool
Authors: Hackeng Wenzel M. , Dreijerink Koen M.A. , de Leng Wendy W.J. , Morsink Folkert H.M. , Valk Gerlof D. , Vriens Menno R. , Offerhaus G. Johan A. , Geisenberger Christoph , Brosens Lodewijk A.A.
Published: April 2023

Cohort information
Supplemental Figure Legends from Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma
Authors: Alewine Christine , Ahmad Mehwish , Peer Cody J. , Hu Zishuo I. , Lee Min-Jung , Yuno Akira , Kindrick Jessica D. , Thomas Anish , Steinberg Seth M. , Trepel Jane B. , Figg William D. , Hassan Raffit , Pastan Ira
Published: April 2023

Supplemental Figure Legends
Supplemental Figure 5 from Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence
Authors: Xie Hao , Mahoney Douglas W. , Foote Patrick H. , Burger Kelli N. , Doering Karen A. , Taylor William R. , Then Sara S. , Cao Xiaoming , McGlinch Maria , Berger Calise K. , Wu Tsung-Teh , Hubbard Joleen M. , Allawi Hatim T. , Kaiser Michael W. , Lidgard Graham P. , Ahlquist David A. , Kisiel John B.
Published: April 2023

Supplemental Figure 5: No difference in carcinoembryonic antigen (CEA) values in nanograms per milliliter (ng/mL) was seen in a comparison of available clinical serum versus experimental plasma samples from colorectal cancer patients with no evidence of disease (NED) or with recurrent & metastatic disease. Clinical serum measurements of CEA were not available for controls.
Figure S1 from A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers
Authors: Paik Paul K. , Kim Rachel K. , Ahn Linda , Plodkowski Andrew J. , Ni Ai , Donoghue Mark T.A. , Jonsson Philip , Villalona-Calero Miguel , Ng Kenneth , McFarland Daniel , Fiore John J. , Iqbal Afsheen , Eng Juliana , Kris Mark G. , Rudin Charles M.
Published: April 2023

Survival plots
Table S1 from Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo
Authors: Anastasiadou Eleni , Seto Anita G. , Beatty Xuan , Hermreck Melanie , Gilles Maud-Emmanuelle , Stroopinsky Dina , Pinter-Brown Lauren C. , Pestano Linda , Marchese Cinzia , Avigan David , Trivedi Pankaj , Escolar Diana M. , Jackson Aimee L. , Slack Frank J.
Published: April 2023

Supplementary table S1
Figure S2 from Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma
Authors: Daemen Anneleen , Cooper Jonathan E. , Myrta Szymon , Wongchenko Matthew J. , Lin Eva , Long Jason E. , Foreman Oded , Modrusan Zora , Tremayne Jarrod R. , de la Cruz Cecile C. , Merchant Mark , Martin Scott E. , Yan Yibing , Junttila Melissa R.
Published: April 2023

Supplemental Figure 2. Biological characterization of the three subtypes in human LUAD.
Supplemental Table 1 from Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial
Authors: Patnaik Amita , Yap Timothy A. , Chung Hyun Cheol , de Miguel Maria J. , Bang Yung-Jue , Lin Chia-Chi , Su Wu-Chou , Italiano Antoine , Chow Kay Hoong , Szpurka Anna M. , Yu Danni , Zhao Yumin , Carlsen Michelle , Schmidt Shelly , Vangerow Burkhard , Gandhi Leena , Xu Xiaojian , Bendell Johanna
Published: April 2023

Baseline characteristics of patients in each dosing group for each arm of the study
Supplemental Figure 1 from Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial
Authors: Patnaik Amita , Yap Timothy A. , Chung Hyun Cheol , de Miguel Maria J. , Bang Yung-Jue , Lin Chia-Chi , Su Wu-Chou , Italiano Antoine , Chow Kay Hoong , Szpurka Anna M. , Yu Danni , Zhao Yumin , Carlsen Michelle , Schmidt Shelly , Vangerow Burkhard , Gandhi Leena , Xu Xiaojian , Bendell Johanna
Published: April 2023

Study design schematic showing the numbers of patients per dosing group
Figure S9 from A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers
Authors: Mathur Divya , Root Adam R. , Bugaj-Gaweda Bozena , Bisulco Stephanie , Tan Xingzhi , Fang Wei , Kearney Jessica C. , Lucas Justin , Guffroy Magali , Golas Jonathan , Rohde Cynthia M. , Stevens Chad , Kamperschroer Cris , Kelleher Kerry , Lawrence-Henderson Rosemary F. , Upeslacis Erik , Yao Johnny , Narula Jatin , LaVallie Edward R. , Fernandez Diane R. , Buetow Bernard S. , Rosfjord Edward , Bloom Laird , King Lindsay E. , Tchistiakova Lioudmila , Nguyen Anhco , Sapra Puja
Published: April 2023

Proposed model for PF-07062119 anti-tumor activity in combination with checkpoint blockade and anti-angiogenesis agents
Supplementary Data from Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC
Authors: Recondo Gonzalo , Bahcall Magda , Spurr Liam F. , Che Jianwei , Ricciuti Biagio , Leonardi Giulia C. , Lo Ying-Chun , Li Yvonne Y. , Lamberti Giuseppe , Nguyen Tom , Milan Marina S.D. , Venkatraman Deepti , Umeton Renato , Paweletz Cloud P. , Albayrak Adem , Cherniack Andrew D. , Price Kristin S. , Fairclough Stephen R. , Nishino Mizuki , Sholl Lynette M. , Oxnard Geoffrey R. , Jänne Pasi A. , Awad Mark M.
Published: April 2023

Supplementary Figure Legends
Supplementary Data from Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC
Authors: Recondo Gonzalo , Bahcall Magda , Spurr Liam F. , Che Jianwei , Ricciuti Biagio , Leonardi Giulia C. , Lo Ying-Chun , Li Yvonne Y. , Lamberti Giuseppe , Nguyen Tom , Milan Marina S.D. , Venkatraman Deepti , Umeton Renato , Paweletz Cloud P. , Albayrak Adem , Cherniack Andrew D. , Price Kristin S. , Fairclough Stephen R. , Nishino Mizuki , Sholl Lynette M. , Oxnard Geoffrey R. , Jänne Pasi A. , Awad Mark M.
Published: April 2023

Supplementary Figures
Figure S3 from A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers
Authors: Mathur Divya , Root Adam R. , Bugaj-Gaweda Bozena , Bisulco Stephanie , Tan Xingzhi , Fang Wei , Kearney Jessica C. , Lucas Justin , Guffroy Magali , Golas Jonathan , Rohde Cynthia M. , Stevens Chad , Kamperschroer Cris , Kelleher Kerry , Lawrence-Henderson Rosemary F. , Upeslacis Erik , Yao Johnny , Narula Jatin , LaVallie Edward R. , Fernandez Diane R. , Buetow Bernard S. , Rosfjord Edward , Bloom Laird , King Lindsay E. , Tchistiakova Lioudmila , Nguyen Anhco , Sapra Puja
Published: April 2023

Quantitative Real-Time PCR based evaluation of gucy2c expression in HCT116 and T84 cells
Supplemental Methods from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma
Authors: Foltz Jennifer A. , Hess Brian T. , Bachanova Veronika , Bartlett Nancy L. , Berrien-Elliott Melissa M. , McClain Ethan , Becker-Hapak Michelle , Foster Mark , Schappe Timothy , Kahl Brad , Mehta-Shah Neha , Cashen Amanda F. , Marin Nancy D. , McDaniels Kristen , Moreno Chaz , Mosior Matthew , Gao Feng , Griffith Obi L. , Griffith Malachi , Wagner Julia A. , Epperla Narendranath , Rock Amy D. , Lee John , Petti Allegra A. , Soon-Shiong Patrick , Fehniger Todd A.
Published: April 2023

Additional Methods
Supplementary File 7: Loco-regional control and survival. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
Authors: de Haan Rosemarie , van den Heuvel Michel M. , van Diessen Judi , Peulen Heike M.U. , van Werkhoven Erik , de Langen Adrianus J. , Lalezari Ferry , Pluim Dick , Verwijs-Janssen Manon , Vens Conchita , Schellens Jan H.M. , Steeghs Neeltje , Verheij Marcel , van Triest Baukelien
Published: April 2023

This file contains details on loco-regional control, progression free survival and overall survival split by treatment arm.
Supplementary File 5: Esophageal Adverse Events. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
Authors: de Haan Rosemarie , van den Heuvel Michel M. , van Diessen Judi , Peulen Heike M.U. , van Werkhoven Erik , de Langen Adrianus J. , Lalezari Ferry , Pluim Dick , Verwijs-Janssen Manon , Vens Conchita , Schellens Jan H.M. , Steeghs Neeltje , Verheij Marcel , van Triest Baukelien
Published: April 2023

This file contains details on all late grade {greater than or equal to} 2 esophageal adverse events (I) and esophageal metabolic activity six weeks post-treatment (II).
Supplementary Data from TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer
Authors: Lehmann Brian D. , Abramson Vandana G. , Sanders Melinda E. , Mayer Erica L. , Haddad Tufia C. , Nanda Rita , Van Poznak Catherine , Storniolo Anna Maria , Nangia Julie R. , Gonzalez-Ericsson Paula I. , Sanchez Violeta , Johnson Kimberly N. , Abramson Richard G. , Chen Sheau-Chiann , Shyr Yu , Arteaga Carlos L. , Wolff Antonio C. , Pietenpol Jennifer A.
Published: April 2023

Supplemental Material
Supplementary Figure S3 from Detection of Aneuploidy in Cerebrospinal Fluid from Patients with Breast Cancer Can Improve Diagnosis of Leptomeningeal Metastases
Authors: Angus Lindsay , Deger Teoman , Jager Agnes , Martens John W.M. , de Weerd Vanja , van Heuvel Irene , van den Bent Martin J. , Sillevis Smitt Peter A.E. , Kros Johan M. , Bindels Eric M.J. , Heitzer Ellen , Sleijfer Stefan , Jongen Joost L.M. , Wilting Saskia M.
Published: April 2023

Combination of mFAST-SeqS z-score and metastatic disease at time of CSF collection.
Supplementary Table 1 from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes
Authors: Estrada-Bernal Adriana , Le Anh T. , Doak Andrea E. , Tirunagaru Vijaya G. , Silva Shevan , Bull Matthew R. , Smaill Jeff B. , Patterson Adam V. , Kim Chul , Liu Stephen V. , Doebele Robert C.
Published: April 2023

Cell lines used in the paper
Supplementary Figure S7 from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes
Authors: Estrada-Bernal Adriana , Le Anh T. , Doak Andrea E. , Tirunagaru Vijaya G. , Silva Shevan , Bull Matthew R. , Smaill Jeff B. , Patterson Adam V. , Kim Chul , Liu Stephen V. , Doebele Robert C.
Published: April 2023

Tarloxotinib inhibits tumor growth of EGFR exon 20 mutant, HER2 gene altered, models in vivo.
Supplementary Figure S3 from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes
Authors: Estrada-Bernal Adriana , Le Anh T. , Doak Andrea E. , Tirunagaru Vijaya G. , Silva Shevan , Bull Matthew R. , Smaill Jeff B. , Patterson Adam V. , Kim Chul , Liu Stephen V. , Doebele Robert C.
Published: April 2023

Tarloxotinib-E inhibits ErbB family members phosphorylation and downstream signaling in EGFR, HER2 and NRG1 driven cell lines.
Supplementary Figure S1 from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes
Authors: Estrada-Bernal Adriana , Le Anh T. , Doak Andrea E. , Tirunagaru Vijaya G. , Silva Shevan , Bull Matthew R. , Smaill Jeff B. , Patterson Adam V. , Kim Chul , Liu Stephen V. , Doebele Robert C.
Published: April 2023

Representation of tarloxotinib conversion to its irreversible EGFR/HER2 inhibitor.
Table S4 from Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer
Authors: Abraham Jim P. , Magee Daniel , Cremolini Chiara , Antoniotti Carlotta , Halbert David D. , Xiu Joanne , Stafford Phillip , Berry Donald A. , Oberley Matthew J. , Shields Anthony F. , Marshall John L. , Salem Mohamed E. , Falcone Alfredo , Grothey Axel , Hall Michael J. , Venook Alan P. , Lenz Heinz-Josef , Helmstetter Anthony , Korn W. Michael , Spetzler David B.
Published: April 2023

Demographics of TRIBE2 RCT cases used in this study compared with the full trial.
Supplementary Tables from Genomic Characterization of de novo Metastatic Breast Cancer
Authors: Garrido-Castro Ana C. , Spurr Liam F. , Hughes Melissa E. , Li Yvonne Y. , Cherniack Andrew D. , Kumari Priti , Lloyd Maxwell R. , Bychkovsky Brittany , Barroso-Sousa Romualdo , Di Lascio Simona , Jain Esha , Files Janet , Mohammed-Abreu Ayesha , Krevalin Max , MacKichan Colin , Barry William T. , Guo Hao , Xia Daniel , Cerami Ethan , Rollins Barrett J. , MacConaill Laura E. , Lindeman Neal I. , Krop Ian E. , Johnson Bruce E. , Wagle Nikhil , Winer Eric P. , Dillon Deborah A. , Lin Nancy U.
Published: April 2023

Tables S1-S12
Figure S7 from Exposure–Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing
Authors: Campagne Olivia , Zhong Bo , Nair Sreenath , Lin Tong , Huang Jie , Onar-Thomas Arzu , Robinson Giles , Gajjar Amar , Stewart Clinton F.
Published: April 2023

Distribution of drug exposures between patients with and without transfusion support
Figure S3 from Exposure–Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing
Authors: Campagne Olivia , Zhong Bo , Nair Sreenath , Lin Tong , Huang Jie , Onar-Thomas Arzu , Robinson Giles , Gajjar Amar , Stewart Clinton F.
Published: April 2023

Goodness-of-fit plots of the PK base model
Figure S1 from Exposure–Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing
Authors: Campagne Olivia , Zhong Bo , Nair Sreenath , Lin Tong , Huang Jie , Onar-Thomas Arzu , Robinson Giles , Gajjar Amar , Stewart Clinton F.
Published: April 2023

PK model structure
Supplementary Data from Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
Authors: Abida Wassim , Campbell David , Patnaik Akash , Shapiro Jeremy D. , Sautois Brieuc , Vogelzang Nicholas J. , Voog Eric G. , Bryce Alan H. , McDermott Ray , Ricci Francesco , Rowe Julie , Zhang Jingsong , Piulats Josep Maria , Fizazi Karim , Merseburger Axel S. , Higano Celestia S. , Krieger Laurence E. , Ryan Charles J. , Feng Felix Y. , Simmons Andrew D. , Loehr Andrea , Despain Darrin , Dowson Melanie , Green Foad , Watkins Simon P. , Golsorkhi Tony , Chowdhury Simon
Published: April 2023

Suppl Table 1
Supplementary Figure S7 from Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
Authors: Greene Sarah , Robbins Yvette , Mydlarz Wojciech K. , Huynh Angel P. , Schmitt Nicole C. , Friedman Jay , Horn Lucas A. , Palena Claudia , Schlom Jeffrey , Maeda Dean Y. , Zebala John A. , Clavijo Paul E. , Allen Clint
Published: April 2023

Supplemental Figure S7. SX-682 treatment does not alter PMN-MDSC suppressive capacity
Supplementary Tables from AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer
Authors: Giffin Michael J. , Cooke Keegan , Lobenhofer Edward K. , Estrada Juan , Zhan Jinghui , Deegen Petra , Thomas Melissa , Murawsky Christopher M. , Werner Jonathan , Liu Siyuan , Lee Fei , Homann Oliver , Friedrich Matthias , Pearson Joshua T. , Raum Tobias , Yang Yajing , Caenepeel Sean , Stevens Jennitte , Beltran Pedro J. , Canon Jude , Coxon Angela , Bailis Julie M. , Hughes Paul E.
Published: April 2023

This file contains Supplementary Tables 1-5
Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 from Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer
Authors: Akcakanat Argun , Zheng Xiaofeng , Cruz Pico Christian X. , Kim Tae-Beom , Chen Ken , Korkut Anil , Sahin Aysegul , Holla Vijaykumar , Tarco Emily , Singh Gopal , Damodaran Senthil , Mills Gordon B. , Gonzalez-Angulo Ana Maria , Meric-Bernstam Funda
Published: April 2023

Supplementary Figures 1-5
Supplementary Table 1 from Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial
Authors: McCartney Amelia , Bonechi Martina , De Luca Francesca , Biagioni Chiara , Curigliano Giuseppe , Moretti Erica , Minisini Alessandro Marco , Bergqvist Mattias , Benelli Matteo , Migliaccio Ilenia , Galardi Francesca , Risi Emanuela , De Santo Irene , Romagnoli Dario , Biganzoli Laura , Di Leo Angelo , Malorni Luca
Published: April 2023

Baseline characteristics of studied c-TREnd biomarker population - including all patients with at least one sample available for analysis at any timepoint(s), compared to the overall original TREnd cohort. Fisher exact test was used to calculate p-values. *Denotes patients included in intention-to-treat population of TREnd, despite breach of eligibility criteria (discovered post-enrolment).
Supplemental Figure 1 from Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial
Authors: Loree Jonathan M. , Dowers Anthony , Tu Dongsheng , Jonker Derek J. , Edelstein Daniel L. , Quinn Hannah , Holtrup Frank , Price Timothy , Zalcberg John R. , Moore Malcolm J. , Karapetis Christos S. , O'Callaghan Chris J. , Waring Paul , Kennecke Hagen F. , Hamilton Stanley R. , Kopetz Scott
Published: April 2023

Supplemental Figure 1
Supplementary Table-7 from Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting
Authors: Morris Jeffrey S. , Luthra Rajyalakshmi , Liu Yusha , Duose Dzifa Y. , Lee Wonyul , Reddy Neelima G. , Windham Justin , Chen Huiqin , Tong Zhimin , Zhang Baili , Wei Wei , Ganiraju Manyam , Broom Bradley M. , Alvarez Hector A. , Mejia Alicia , Veeranki Omkara , Routbort Mark J. , Morris Van K. , Overman Michael J. , Menter David , Katkhuda Riham , Wistuba Ignacio I. , Davis Jennifer S. , Kopetz Scott , Maru Dipen M.
Published: April 2023

Classification accuracy on validation data set, the entire set (V2), out-of-sample prediction (V2o), Affymetrix subset (V2a), and TCGA RNAseq subset (TCGA) for various methods as function of number of genes.
Supplementary Table 5 from Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases
Authors: Kanikarla Marie Preeti , Haymaker Cara , Parra Edwin Roger , Kim Young Uk , Lazcano Rossana , Gite Swati , Lorenzini Daniele , Wistuba Ignacio I. , Tidwell Rebecca S. Slack , Song Xiaofei , Foo Wai Chin , Maru Dipen M. , Chun Yun Shin , Futreal Andy , Kee Bryan , Menter David , Solis Luisa , Tzeng Ching-Wei , Parseghian Christine , Raghav Kanwal , Morris Van , Chang Chia-Chi , Jenq Robert , Tam Alda , Bernatchez Chantale , Kopetz Scott , Vauthey Jean-Nicolas , Overman Michael J.
Published: April 2023

RFS long and short microbiome-taxa abundance
Supplementary Table 4 from Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases
Authors: Kanikarla Marie Preeti , Haymaker Cara , Parra Edwin Roger , Kim Young Uk , Lazcano Rossana , Gite Swati , Lorenzini Daniele , Wistuba Ignacio I. , Tidwell Rebecca S. Slack , Song Xiaofei , Foo Wai Chin , Maru Dipen M. , Chun Yun Shin , Futreal Andy , Kee Bryan , Menter David , Solis Luisa , Tzeng Ching-Wei , Parseghian Christine , Raghav Kanwal , Morris Van , Chang Chia-Chi , Jenq Robert , Tam Alda , Bernatchez Chantale , Kopetz Scott , Vauthey Jean-Nicolas , Overman Michael J.
Published: April 2023

Post treatment and pre treatment DEG in RFS long vs short
Supplementary figure legend from Everolimus Inhibits the Progression of Ductal Carcinoma In Situ to Invasive Breast Cancer Via Downregulation of MMP9 Expression
Authors: Chen Guang , Ding Xiao-Fei , Pressley Kyle , Bouamar Hakim , Wang Bingzhi , Zheng Guixi , Broome Larry E. , Nazarullah Alia , Brenner Andrew J. , Kaklamani Virginia , Jatoi Ismail , Sun Lu-Zhe
Published: April 2023

Supplementary figure legend
eFigure5 from Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
Authors: Barroso-Sousa Romualdo , Keenan Tanya E. , Pernas Sonia , Exman Pedro , Jain Esha , Garrido-Castro Ana C. , Hughes Melissa , Bychkovsky Brittany , Umeton Renato , Files Janet L. , Lindeman Neal I. , MacConaill Laura E. , Hodi F. Stephen , Krop Ian E. , Dillon Deborah , Winer Eric P. , Wagle Nikhil , Lin Nancy U. , Mittendorf Elizabeth A. , Van Allen Eliezer M. , Tolaney Sara M.
Published: April 2023

Kaplan-Meier curves for overall survival for high TMB {greater than or equal to}7 and {greater than or equal to}10 mutations/Mb and PTEN alterations in non-ICI-treated mTNBC. Overall survival by (A) tumor mutational burden <7 vs. {greater than or equal to}7 mutations/megabase; (B) tumor mutational burden <10 vs. {greater than or equal to}10 mutations/megabase, and (C) PTEN alteration (absent vs. present).
Figure S11 from CamGFR v2: A New Model for Estimating the Glomerular Filtration Rate from Standardized or Non-standardized Creatinine in Patients with Cancer
Authors: Williams Edward H. , Flint Thomas R. , Connell Claire M. , Giglio Daniel , Lee Hassal , Ha Taehoon , Gablenz Eva , Bird Nicholas J. , Weaver James M.J. , Potts Harry , Whitley Cameron T. , Bookman Michael A. , Lynch Andy G. , Meyer Hannah V. , Tavaré Simon , Janowitz Tobias
Published: April 2023

CamGFR v2 App Screenshot
Supplementary Figure Legends from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
Authors: Pietrantonio Filippo , Lobefaro Riccardo , Antista Maria , Lonardi Sara , Raimondi Alessandra , Morano Federica , Mosconi Stefania , Rimassa Lorenza , Murgioni Sabina , Sartore-Bianchi Andrea , Tomasello Gianluca , Longarini Raffaella , Farina Gabriella , Petrelli Fausto , Gori Stefania , Randon Giovanni , Corallo Salvatore , Pagani Filippo , Guarini Vincenzo , Palermo Federica , Martinetti Antonia , Macagno Marco , Barault Ludovic , Perrone Federica , Tamborini Elena , Milione Massimo , Di Nicolantonio Federica , Di Maio Massimo , Fucà Giovanni , Di Bartolomeo Maria , de Braud Filippo
Published: April 2023

Supplementary Figure Legends
Figure S6 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
Authors: Tukachinsky Hanna , Madison Russell W. , Chung Jon H. , Gjoerup Ole V. , Severson Eric A. , Dennis Lucas , Fendler Bernard J. , Morley Samantha , Zhong Lei , Graf Ryon P. , Ross Jeffrey S. , Alexander Brian M. , Abida Wassim , Chowdhury Simon , Ryan Charles J. , Fizazi Karim , Golsorkhi Tony , Watkins Simon P. , Simmons Andrew , Loehr Andrea , Venstrom Jeffrey M. , Oxnard Geoffrey R.
Published: April 2023

Ratio of detection rates in liquid versus tissue.
Supplementary fig 3 from Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy
Authors: Wang Chunmeng , Liu Yang , Dong Liang , Li Xiang , Yang Qingming , Brock Malcolm V. , Mei Qian , Liu Jiejie , Chen Meixia , Shi Fengxia , Liu Miao , Nie Jing , Han Weidong
Published: April 2023

Figure 3. Ratio of peripheral memory T-cells during camrelizumab monotherapy and decitabine-plus-camrelizumab therapy.
Table S1, S2 from ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non–Small Cell Lung Cancer
Authors: Okura Naoko , Nishioka Naoya , Yamada Tadaaki , Taniguchi Hirokazu , Tanimura Keiko , Katayama Yuki , Yoshimura Akihiro , Watanabe Satoshi , Kikuchi Toshiaki , Shiotsu Shinsuke , Kitazaki Takeshi , Nishiyama Akihiro , Iwasaku Masahiro , Kaneko Yoshiko , Uchino Junji , Uehara Hisanori , Horinaka Mano , Sakai Toshiyuki , Tanaka Kohei , Kozaki Ryohei , Yano Seiji , Takayama Koichi
Published: April 2023

Table S1, S2
Table S5 from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
Authors: Compte Marta , Harwood Seandean L. , Erce-Llamazares Ainhoa , Tapia-Galisteo Antonio , Romero Eduardo , Ferrer Irene , Garrido-Martin Eva M. , Enguita Ana B. , Ochoa Maria C. , Blanco Belén , Oteo Marta , Merino Nekane , Nehme-Álvarez Daniel , Hangiu Oana , Domínguez-Alonso Carmen , Zonca Manuela , Ramírez-Fernández Angel , Blanco Francisco J. , Morcillo Miguel A. , Muñoz Ines G. , Melero Ignacio , Rodriguez-Peralto José L. , Paz-Ares Luis , Sanz Laura , Alvarez-Vallina Luis
Published: April 2023

Kinetic constants
Figure S2 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Authors: Karn Thomas , Meissner Tobias , Weber Karsten E. , Solbach Christine , Denkert Carsten , Engels Knut , Fasching Peter A. , Sinn Bruno V. , Schrader Iris , Budczies Jan , Marmé Frederik , Müller Volkmar , Holtrich Uwe , Gerber Bernd , Schem Christian , Young Brandon M. , Hanusch Claus , Stickeler Elmar , Huober Jens , van Mackelenbergh Marion , Leyland-Jones Brian , Fehm Tanja , Nekljudova Valentina , Untch Michael , Loibl Sibylle
Published: April 2023

Immunohistochemical validation of hypoxia signature
Figure S1 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Authors: Karn Thomas , Meissner Tobias , Weber Karsten E. , Solbach Christine , Denkert Carsten , Engels Knut , Fasching Peter A. , Sinn Bruno V. , Schrader Iris , Budczies Jan , Marmé Frederik , Müller Volkmar , Holtrich Uwe , Gerber Bernd , Schem Christian , Young Brandon M. , Hanusch Claus , Stickeler Elmar , Huober Jens , van Mackelenbergh Marion , Leyland-Jones Brian , Fehm Tanja , Nekljudova Valentina , Untch Michael , Loibl Sibylle
Published: April 2023

Flow of samples through the study (CONSORT).
Supplementary Video 3 from A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy
Authors: Santich Brian H. , Cheal Sarah M. , Ahmed Mahiuddin , McDevitt Michael R. , Ouerfelli Ouathek , Yang Guangbin , Veach Darren R. , Fung Edward K. , Patel Mitesh , Burnes Vargas Daniela , Malik Aiza A. , Guo Hong-Fen , Zanzonico Pat B. , Monette Sebastien , Michel Adam O. , Rudin Charles M. , Larson Steven M. , Cheung Nai K.
Published: April 2023

2-step IgG-PRIT imaging by PET/CT (no CA)
Figure S2 from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
Authors: Compte Marta , Harwood Seandean L. , Erce-Llamazares Ainhoa , Tapia-Galisteo Antonio , Romero Eduardo , Ferrer Irene , Garrido-Martin Eva M. , Enguita Ana B. , Ochoa Maria C. , Blanco Belén , Oteo Marta , Merino Nekane , Nehme-Álvarez Daniel , Hangiu Oana , Domínguez-Alonso Carmen , Zonca Manuela , Ramírez-Fernández Angel , Blanco Francisco J. , Morcillo Miguel A. , Muñoz Ines G. , Melero Ignacio , Rodriguez-Peralto José L. , Paz-Ares Luis , Sanz Laura , Alvarez-Vallina Luis
Published: April 2023

Binding assays of 4-1BB IgG and urelumab.
Figure S11 from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
Authors: Compte Marta , Harwood Seandean L. , Erce-Llamazares Ainhoa , Tapia-Galisteo Antonio , Romero Eduardo , Ferrer Irene , Garrido-Martin Eva M. , Enguita Ana B. , Ochoa Maria C. , Blanco Belén , Oteo Marta , Merino Nekane , Nehme-Álvarez Daniel , Hangiu Oana , Domínguez-Alonso Carmen , Zonca Manuela , Ramírez-Fernández Angel , Blanco Francisco J. , Morcillo Miguel A. , Muñoz Ines G. , Melero Ignacio , Rodriguez-Peralto José L. , Paz-Ares Luis , Sanz Laura , Alvarez-Vallina Luis
Published: April 2023

Serum stability of the 4-1BBN/CEGFR trimerbody.
Table S2 from Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors
Authors: Spicer James , Marabelle Aurélien , Baurain Jean-Francois , Jebsen Nina Louise , Jøssang Dag Erik , Awada Ahmad , Kristeleit Rebecca , Loirat Delphine , Lazaridis George , Jungels Christiane , Brunsvig Paal , Nicolaisen Berit , Saunders Andrew , Patel Hamina , Galon Jérôme , Hermitte Fabienne , Camilio Ketil André , Mauseth Brynjar , Sundvold Vibeke , Sveinbjørnsson Baldur , Rekdal Øystein
Published: April 2023

Table S2 shows abscopal effects in a single non-injected lesion by percent change from baseline, as well as the location of the lesion.